BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 38474186)

  • 1. Ubiquitination and deubiquitination in the regulation of N
    Zhao Y; Huang J; Zhao K; Li M; Wang S
    J Mol Med (Berl); 2024 Mar; 102(3):337-351. PubMed ID: 38289385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
    Xu M; Li S
    Cancer Lett; 2024 May; 593():216969. PubMed ID: 38768681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 at the crossroad between RNA metabolism and immunosuppression.
    Arthur A; Nejmi S; Franchini DM; Espinos E; Millevoi S
    Trends Mol Med; 2024 May; ():. PubMed ID: 38824002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
    Kim SB; Hwang S; Cha JY; Lee HJ
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
    Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
    Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
    Jiang Y; Hong K; Zhao Y; Xu K
    Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy.
    Hou B; Chen T; Zhang H; Li J; Wang P; Shang G
    Front Immunol; 2023; 14():1123244. PubMed ID: 36733484
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.